The diagnostic company has been at the forefront of bringing latest technological advancements to India
As India continues to battle a virulent second wave of the Covid-19 pandemic, the healthcare infrastructure is straining to cope with the load of new cases. Aiding them in this strenuous task, right from the beginning, are medical laboratories which have undertaken the job of responsible testing and diagnosis. One of the first few labs to be commissioned for Covid-19 testing, Metropolis Healthcare, a leading chain of Indian diagnostic companies, has been in the forefront of the Covid-19 battle.
The company, which has its central laboratory at Mumbai, was first established as ‘Dr Sushil Shah’s Laboratory’ by Dr Sushil Kanubhai Shah in his garage in 1981. It rapidly gained a good name and began clinical research services in 1992. Dr Sushil Shah wished to bring to the Indian people the latest technological advancements; and reportedly, his lab was one of the first in India to
Markets likely to be volatile on global cues; HDFC Bank, DHFL in focus
Premium
3 min read
Share Via
Read Full Story
Markets are likely to be volatile on Monday following global cues. Trends in SGX Nifty suggest a negative opening of Indian benchmark indices. On Friday, the BSE Sensex closed at 49,034.67, down 549.49 points or 1.11%. The Nifty closed at 14,433.70, down 161.90 points or 1.11%
Asian share markets retreated from highs on Monday as disappointing news on US consumer spending tempered risk sentiment ahead of a closely-watched reading on the health of the Chinese economy.
TRENDING STORIESSee All
1 min read
Premium
2 min read
Premium
Extending fall for the second straight session, Sensex ended 470 points lower at 48,564 and Nifty fell by 152 points to 14,281. In the last two sessions, Sensex has lost 1,019 points and Nifty is down 313 points
Metropolis Healthcare, a leading diagnostic service provider, is set to acquire Chennai-based Dr Ganesan’s Hitech Diagnostic Centre Pvt Ltd for a cash consideration of Rs 511 crore. Metropolis will acquire 100 per cent equity of Dr Ganesan’s Hitech Diagnostic Centre in a cash and stock deal. The entity is a debt free company and will issue up to 495,000 equity shares of face value Rs 2 each on preferential basis, subject to shareholders approval, to the promoter group of Hitech. The cash consideration will be funded through internal accruals and a debt of up to Rs 300 crore. Dr Ganesan, promoter and founder, will be part of the leadership team for the next few years to enable a smooth transition and integration with Metropolis.